Wellington Management Group LLP Acquires 701,064 Shares of Vericel Co. (NASDAQ:VCEL)

Wellington Management Group LLP grew its position in Vericel Co. (NASDAQ:VCEL - Free Report) by 119.3% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 1,288,921 shares of the biotechnology company's stock after acquiring an additional 701,064 shares during the period. Wellington Management Group LLP owned 2.61% of Vericel worth $70,775,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also bought and sold shares of VCEL. Stifel Financial Corp lifted its position in Vericel by 40.0% in the 3rd quarter. Stifel Financial Corp now owns 28,073 shares of the biotechnology company's stock valued at $1,186,000 after acquiring an additional 8,020 shares in the last quarter. Geode Capital Management LLC lifted its holdings in shares of Vericel by 0.8% during the 3rd quarter. Geode Capital Management LLC now owns 1,154,053 shares of the biotechnology company's stock worth $48,768,000 after acquiring an additional 9,613 shares during the last quarter. Louisiana State Employees Retirement System lifted its stake in Vericel by 0.8% in the fourth quarter. Louisiana State Employees Retirement System now owns 23,900 shares of the biotechnology company's stock worth $1,312,000 after purchasing an additional 200 shares during the last quarter. Park Avenue Securities LLC purchased a new position in Vericel during the 4th quarter valued at about $280,000. Finally, Proficio Capital Partners LLC bought a new stake in shares of Vericel during the 4th quarter valued at about $956,000.

Insider Buying and Selling at Vericel

In other Vericel news, Director Robert L. Md Zerbe sold 2,500 shares of the company's stock in a transaction on Wednesday, February 5th. The stock was sold at an average price of $62.50, for a total value of $156,250.00. Following the sale, the director now directly owns 26,595 shares in the company, valued at $1,662,187.50. This represents a 8.59 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Dominick Colangelo sold 26,592 shares of the company's stock in a transaction on Thursday, March 13th. The shares were sold at an average price of $45.78, for a total value of $1,217,381.76. Following the transaction, the chief executive officer now directly owns 259,997 shares in the company, valued at $11,902,662.66. This trade represents a 9.28 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 34,092 shares of company stock valued at $1,683,582 in the last 90 days. 5.20% of the stock is currently owned by corporate insiders.

Remove Ads

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on the company. StockNews.com raised Vericel from a "sell" rating to a "hold" rating in a research report on Saturday, March 8th. HC Wainwright restated a "buy" rating and issued a $60.00 price target on shares of Vericel in a research note on Friday, February 28th. Truist Financial restated a "buy" rating and issued a $61.00 price target (down from $67.00) on shares of Vericel in a research note on Monday, March 3rd. Stephens reiterated an "overweight" rating and set a $65.00 target price on shares of Vericel in a research report on Wednesday, January 15th. Finally, Canaccord Genuity Group increased their price target on Vericel from $64.00 to $67.00 and gave the company a "buy" rating in a report on Monday, February 3rd. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $62.29.

Vericel Trading Down 5.8 %

NASDAQ:VCEL traded down $2.55 during mid-day trading on Thursday, reaching $41.69. 105,395 shares of the stock were exchanged, compared to its average volume of 385,958. The business has a fifty day moving average price of $49.92 and a 200 day moving average price of $51.46. The firm has a market capitalization of $2.09 billion, a PE ratio of 703.32 and a beta of 1.61. Vericel Co. has a 1-year low of $37.76 and a 1-year high of $63.00.

About Vericel

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.